The Max Foundation welcomes John Menapace as CFO/VP of Administration

The Max Foundation welcomes John Menapace as CFO/VP of Administration

We are delighted to announce that John Menapace has joined the Max Foundation as CFO/VP of Administration.

John brings demonstrated business leadership to his new role with a background comprising more than 20 years of experience in driving growth and profitability, across Fortune 50, Big 5, non-profit, and start-up companies.  His prior roles include positions of increasing responsibility within such leading organizations as the  American Red Cross, Clinton Health Access Initiative, and Kedrion Biopharma.  Most recently, he was CFO of The Floating Hospital in New York, one of New York City’s oldest healthcare charities with over 150 years of service to the neediest New Yorkers.

“I feel privileged to be joining The Max Foundation team,” says John. “Having worked in several charitable organizations, I am familiar with the Max Foundation’s lifesaving mission of acting as a bridge between patients and treatment while focusing on those no one else is helping. I am honored to be a part of this deeply humanitarian effort and look forward to actively supporting and working towards fulfilling our near- and long-term goals.”

 “We are at a pivotal period of growth and expansion at the Max Foundation, adds Pat Garcia-Gonzales, CEO of the Max Foundation.  “With John’s richly diverse experience including enterprise transformation and creating value across international markets, he is well suited to lead us into this next phase of growth and evolution as we strategically expand our external partnerships and internal talent”.

We’re excited about the depth and caliber of John’s background and look forward to his contributions as we further extend the Max Foundation’s mission of ensuring safe, high-impact medicine for all patients around the globe.

Please join us in welcoming John Menapace to the Max Foundation and wishing him much success.

The Max Foundation is a leading global health nonprofit organization dedicated to accelerating health equity. For 28 years, Max has pioneered practical, scalable, high-quality solutions to bring life-extending treatments and patient-centered health care to more than 100,000 people living with cancer and critical illness in low- and middle-income countries. Max believes in a world where all people can access high-impact medicines, where geography is not destiny, and where everyone can strive for health with dignity and with hope.

Related Articles

  • The Max Foundation and International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Partner to Enhance the Care of CLL in Low- and Middle-Income Countries

    The Max Foundation and International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Partner to Enhance the Care of CLL in Low- and Middle-Income Countries

    iwCLL to provide training, medical, and programmatic guidance to support implementation of access program for innovative CLL therapy in 29 LMICs over the next three years SEATTLE, Washington – October 10, 2023 – The Max Foundation (Max), a global nonprofit organization dedicated to accelerating health equity by delivering medication, technology, and supportive services to patients….

  • Pat Garcia-Gonzalez Receives Outstanding Contribution to Cancer Control Award by UICC

    Pat Garcia-Gonzalez Receives Outstanding Contribution to Cancer Control Award by UICC

    The Max Foundation CEO recognized for unwavering dedication to global, widespread health equity

  • New study confirms an excellent survival rate of cancer patients in a medication donation program

    New study confirms an excellent survival rate of cancer patients in a medication donation program

    A new study led by Boston University School of Public Health, The Max Foundation, and Novartis Oncology found that chronic myeloid leukemia (CML) patients taking first-line treatment in low- and middle-income countries (LMICs) as part of the Glivec International Patient Assistance Program (GIPAP) have survival rates that compare favorably to those of CML patients receiving treatment in high-income countries.